Emerging treatments for ulcerative colitis: a systematic review.

about

Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification

P2860

Q57156865-CB0EAC96-9F47-4B95-9C27-7B7E27597D59

P2860

Emerging treatments for ulcerative colitis: a systematic review.

Item

http://www.wikidata.org/entity/Q39306383

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Emerging treatments for ulcerative colitis: a systematic review.

@en

Emerging treatments for ulcerative colitis: a systematic review.

@nl

type

Item

label

Emerging treatments for ulcerative colitis: a systematic review.

@en

Emerging treatments for ulcerative colitis: a systematic review.

@nl

prefLabel

Emerging treatments for ulcerative colitis: a systematic review.

@en

Emerging treatments for ulcerative colitis: a systematic review.

@nl

P1476

Emerging treatments for ulcerative colitis: a systematic review

@en

P2093

Alexandros G Tassos

http://www.w3.org/2001/XMLSchema#string

Antonis A Kousoulis

http://www.w3.org/2001/XMLSchema#string

Eftychia E Bosdelekidou

http://www.w3.org/2001/XMLSchema#string

Konstantinos P Economopoulos

http://www.w3.org/2001/XMLSchema#string

Pavlos T Texakalidis

http://www.w3.org/2001/XMLSchema#string

Sotiria Maria Iliopoulou

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

Vitamin D as a therapy for colitis: a systematic review

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Unravelling the pathogenesis of inflammatory bowel disease

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.

P304

923-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00365521.2017.1326163

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Damianos Kokkinidis

P577

2017-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28503977

http://www.w3.org/2001/XMLSchema#string

Emerging treatments for ulcerative colitis: a systematic review.

about

P2860

P2860

Emerging treatments for ulcerative colitis: a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698